8-K: Kura Oncology Announces Positive Results and Strategic Collaboration, Bolstering AML Program

Kura Oncology reports positive topline results from its ziftomenib trial in R/R NPM1-mutant AML, anticipates NDA submission, and highlights a strategic collaboration with Kyowa Kirin.

Summary

• Kura Oncology announced its financial results for the fourth quarter and full year 2024, along with a corporate update.
• The KOMET-001 registrational trial of ziftomenib in R/R NPM1-mutant AML achieved its primary endpoint.
• Kura reached alignment with the FDA and EMA on key aspects of the KOMET-017 protocol, including the use of MRD-negative CR endpoint for potential U.S. accelerated approval in the frontline intensive chemotherapy trial.
• Topline MRD-negative CR results from the KOMET-017-IC Phase 3 trial are anticipated in 2028.
• Multiple data presentations for ziftomenib and pipeline programs are expected throughout 2025.
• The company has $727.4 million in cash, which, along with anticipated collaboration agreement payments, is expected to support ziftomenib commercialization through the frontline AML combination setting.
• Collaboration revenue from the Kyowa Kirin partnership for the fourth quarter and full year 2024 was $53.9 million.
• Research and development expenses for the full year 2024 were $170.0 million.
• General and administrative expenses for the full year 2024 were $77.1 million.
• Net loss for the full year 2024 was $174.0 million.
• The company believes its cash, cash equivalents, and short-term investments will be sufficient to fund operating expenses into 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with successful trial results, a strategic collaboration, and a strong cash position. While there are increased expenses and a net loss, the overall tone is optimistic due to the clinical and strategic advancements.

Positives

• Positive topline results from the KOMET-001 trial in R/R NPM1-mutant AML.
• Alignment with FDA and EMA on key aspects of the KOMET-017 protocol.
• Encouraging clinical data from the KOMET-007 Phase 1 trial.
• Global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib.
• Strong cash position of $727.4 million to fund operations into 2027.
• Preclinical data supports ziftomenib's potential in treating GIST.

Negatives

• Net loss for the full year 2024 was $174.0 million, higher than the $152.6 million loss in the prior year.
• Research and development expenses increased to $170.0 million for the full year 2024, compared to $115.2 million in the prior year.
• General and administrative expenses increased to $77.1 million for the full year 2024, compared to $50.6 million in the prior year.

Risks

• The company faces risks associated with clinical trials, regulatory filings, and reliance on third parties.
• There are risks associated with reliance on outside financing to meet capital requirements.
• The company acknowledges the general risks associated with discovering, developing, and commercializing drugs.

Future Outlook

Kura Oncology expects to submit an NDA for ziftomenib in R/R NPM1-m AML in the second quarter of 2025 and believes its current cash position, along with anticipated collaboration funding, will support its ziftomenib AML program through commercialization in the 1L combination setting.

Management Comments

• We are very pleased the KOMET-001 registrational trial achieved its primary endpoint.
• We look forward to sharing topline data at an upcoming medical conference and expect to submit a New Drug Application (NDA) in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML) next quarter, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
• Given this unmet need, we are pleased to have reached alignment with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on key aspects of our Phase 3 trials, including the use of minimum residual disease (MRD)-negative complete response (CR) as a primary endpoint for potential accelerated approval in the U.S., with topline results anticipated in 2028.
• Our KOMET-017 trial is breaking new ground, and we and our partners at Kyowa Kirin are working as rapidly as possible to bring ziftomenib to AML patients worldwide.

Industry Context

Kura Oncology's progress with ziftomenib and its collaboration with Kyowa Kirin position it as a key player in the precision medicine approach to treating AML, addressing significant unmet needs in both relapsed/refractory and frontline settings. The focus on MRD-negative CR as an endpoint reflects a growing trend in hematologic oncology towards more sensitive measures of treatment response.

Comparison to Industry Standards

• Kura's approach to AML treatment with ziftomenib, a menin inhibitor, aligns with the industry's focus on targeted therapies for specific genetic mutations.
• Companies like Agios Pharmaceuticals (now part of Servier) with Tibsovo (ivosidenib) and Enasidenib (Idhifa) have pioneered targeted therapies for AML with IDH1/2 mutations, demonstrating the potential of precision medicine in this space.
• Kura's collaboration with Kyowa Kirin mirrors similar partnerships in the industry, such as the collaboration between BeiGene and Amgen to develop and commercialize oncology drugs.
• The use of MRD-negative CR as a primary endpoint in clinical trials is becoming increasingly common in hematologic malignancies, reflecting a shift towards more stringent measures of treatment efficacy, similar to approaches used by companies like AbbVie and Roche in their lymphoma trials.

Stakeholder Impact

• Shareholders will likely react positively to the positive trial results and strategic collaboration.
• Employees may experience increased job security and opportunities due to the company's strong financial position and pipeline progress.
• Patients with AML and GIST may benefit from the development of new treatment options.
• The collaboration with Kyowa Kirin may strengthen relationships with suppliers and partners.

Next Steps

• Submit an NDA for ziftomenib in R/R NPM1-m AML in the second quarter of 2025.
• Present topline data from KOMET-001 Phase 2 registration-directed trial in R/R NPM1-m AML in the second quarter of 2025.
• Present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with intensive chemotherapy (7+3) at a medical meeting in the second quarter of 2025.
• Initiate the KOMET-015 trial evaluating ziftomenib and imatinib in patients with advanced GIST in the first half of 2025.
• Initiate two independent Phase 3 registration-enabling trials in 1L intensive (KOMET-017-IC) and non-intensive (KOMET-017-NIC) AML in the second half of 2025.
• Present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with venetoclax and azacitidine at a medical meeting in the second half of 2025.
• Nominate a development candidate for next-generation menin inhibitor program in diabetes in mid-2025.
• Initiate one or more expansion cohorts of KO-2806 and cabozantinib in patients with advanced renal cell carcinoma in the first half of 2025.
• Present data from the Phase 1 monotherapy dose escalation of KO-2806 in patients with RAS mutations in the second half of 2025.
• Present data from the Phase 1 trial evaluating KO-2806 and cabozantinib in patients with renal cell carcinoma in the second half of 2025.
• Present data from the dose escalation portion of KURRENT-HN trial evaluating tipifarnib and alpelisib in PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC) in the second half of 2025.

Key Dates